Mechanisms and Modulation of Accelerated Atherosclerosis in Clonal Hematopoiesis

克隆造血加速动脉粥样硬化的机制和调节

基本信息

  • 批准号:
    10590675
  • 负责人:
  • 金额:
    $ 65.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract With age, humans can accumulate leukocyte clones in blood that arise from somatic mutations in bone marrow stem cells that enhance expansion: clonal hematopoiesis of indeterminate potential (CHIP). Mutations in DNMT3A and TET2 account for the plurality of these clones. CHIP confers highly elevated cardiovascular (CV) risk, independent of traditional risk factors. We have found accelerated atherogenesis and the involvement of IL-1 and IL-6 in mice with myeloid loss of Tet2 or Dnmt3a function and that genetically reduced IL-6 signaling abrogates the elevated CV risk in humans with DNMT3A or TET2 CHIP. Analyses of our CANTOS trial showed greater efficacy of IL-1β inhibition in humans with DNMT3A or TET2 CHIP. These results point the way to a genotype-directed allocation of therapy, an approach that has transformed oncology but remains aspirational in atherosclerosis. The roles of classical vs. trans IL-6 signaling in atherothrombosis requires further study due to conflicting evidence. Specific aim 1 will test the hypothesis that atherosclerotic mice that mimic CHIP due to myeloid deficiency in Dnmt3a treated with an antibody that interrupts global IL-6 signaling by neutralizing IL-6 receptor α (IL-6r, CD126) have decreased atherosclerosis and inflammation within the lesions, blood and other organs as gauged in part by single-cell RNA sequencing (scRNA-seq). We further hypothesize that IL-6r inhibition will limit expansion of the mutant clone. Specific aim 2 will probe the role of classical vs. trans IL-6 signaling in myeloid cells in accelerated atherogenesis in CHIP using Il6rflox/flox/Lyz2-Cre mice bone marrow chimeric LDLR-/- mice (to block leukocyte classical signaling), and administration of a gp130-IgG1-Fc chimeric protein (to block trans signaling) using similar procedures and endpoints. The results will illuminate the controversy and unsettled science regarding the contributions of classical and trans IL-6 signaling to atherogenesis. Specific aim 3. Our preliminary experiments show that female myeloidTet2-/-Ldlr-/- mice have greater acceleration of atherogenesis than Tet2+/+ Ldlr-/- male mice and, unlike their male counterparts, show reduced atherogenesis with IL-1β neutralization. We will localize where this sex difference operates in the inflammasome–IL-1β–IL-6 pathway, and test the hypothesis that female Dnmt3a-/-Ldlr-/- mice have greater response to IL-6r inhibition than males. We will probe mechanisms by gonadal ablation experiments and by analysis of scRNA-seq data, which in preliminary data shows IL-1β expression in resident macrophages cells from atheroma from Tet2-/- females but not males. This work will deepen understanding of the mechanisms of accelerated atherosclerosis in CHIP. Our new pilot clinical data show that an anti-IL-6 antibody can mute inflammation in humans. Thus, the work proposed here will provide an indispensable step toward validating and furnishing the fundamental basis of an immediately translatable targeted therapeutic strategy based on CHIP genotype.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter Libby其他文献

Peter Libby的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter Libby', 18)}}的其他基金

Role of eosinophil cationic proteins in cardiac hypertrophy
嗜酸性粒细胞阳离子蛋白在心脏肥大中的作用
  • 批准号:
    10735136
  • 财政年份:
    2023
  • 资助金额:
    $ 65.04万
  • 项目类别:
Mechanisms and Modulation of Accelerated Atherosclerosis in Clonal Hematopoiesis
克隆造血加速动脉粥样硬化的机制和调节
  • 批准号:
    10418315
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
Role of Mast cells in Alzheimer's Disease
肥大细胞在阿尔茨海默病中的作用
  • 批准号:
    10565862
  • 财政年份:
    2020
  • 资助金额:
    $ 65.04万
  • 项目类别:
Novel mechanisms of the thrombotic complications of atherosclerosis
动脉粥样硬化血栓并发症的新机制
  • 批准号:
    9977702
  • 财政年份:
    2019
  • 资助金额:
    $ 65.04万
  • 项目类别:
Novel mechanisms of the thrombotic complications of atherosclerosis
动脉粥样硬化血栓并发症的新机制
  • 批准号:
    10191002
  • 财政年份:
    2019
  • 资助金额:
    $ 65.04万
  • 项目类别:
Novel mechanisms of the thrombotic complications of atherosclerosis
动脉粥样硬化血栓并发症的新机制
  • 批准号:
    10428552
  • 财政年份:
    2019
  • 资助金额:
    $ 65.04万
  • 项目类别:
REDOX BIOMARKERS
氧化还原生物标志物
  • 批准号:
    8250452
  • 财政年份:
    2011
  • 资助金额:
    $ 65.04万
  • 项目类别:
REDOX BIOMARKERS
氧化还原生物标志物
  • 批准号:
    7975792
  • 财政年份:
    2010
  • 资助金额:
    $ 65.04万
  • 项目类别:
Tissue Analyses
组织分析
  • 批准号:
    7524097
  • 财政年份:
    2007
  • 资助金额:
    $ 65.04万
  • 项目类别:
Tissue Analyses
组织分析
  • 批准号:
    7524090
  • 财政年份:
    2006
  • 资助金额:
    $ 65.04万
  • 项目类别:

相似海外基金

Epigenetic Age Acceleration Impacts Racial and Neighborhood Disparities in Chronic Low Back Pain
表观遗传年龄加速影响慢性腰痛的种族和社区差异
  • 批准号:
    10431156
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
镰状细胞病的表观遗传年龄加速和精神神经症状
  • 批准号:
    10594523
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
Early Life Cardiovascular Disease Risk Factors, Epigenetic Age Acceleration, and Alzheimer's Disease Related Brain Health
生命早期心血管疾病危险因素、表观遗传年龄加速和阿尔茨海默病相关的大脑健康
  • 批准号:
    10706044
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
The pathway from prenatal pregnancy-specific anxiety to offspring ADHD through epigenetic age acceleration DNA methylation and moderators to target intervention: Partner social support
通过表观遗传年龄加速 DNA 甲基化和调节因子从产前妊娠特异性焦虑到后代 ADHD 的途径:伴侣社会支持
  • 批准号:
    475968
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
    Studentship Programs
Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
镰状细胞病的表观遗传年龄加速和精神神经症状
  • 批准号:
    10449461
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
Functional genetic analysis of epigenetic age acceleration and the regulatory landscape of the methylome
表观遗传年龄加速的功能遗传分析和甲基化组的调控景观
  • 批准号:
    10674263
  • 财政年份:
    2022
  • 资助金额:
    $ 65.04万
  • 项目类别:
Perinatal Maternal Anxiety and Offspring ADHD Symptoms: Mediation Through Epigenetic Age Acceleration DNA Methylation
围产期母亲焦虑和后代 ADHD 症状:通过表观遗传年龄加速 DNA 甲基化进行调节
  • 批准号:
    467256
  • 财政年份:
    2021
  • 资助金额:
    $ 65.04万
  • 项目类别:
    Studentship Programs
CAREER: Understanding the Role of Cu-Containing Secondary Phase Particles in Enhancing the Resistance to the Environmental Acceleration to Fatigue in Age-Hardenable Al Alloys
事业:了解含铜第二相颗粒在增强时效硬化铝合金的环境加速疲劳抵抗力方面的作用
  • 批准号:
    1943870
  • 财政年份:
    2020
  • 资助金额:
    $ 65.04万
  • 项目类别:
    Continuing Grant
Breast Cancer Risk Factors and Epigenetic Age Acceleration
乳腺癌危险因素和表观遗传年龄加速
  • 批准号:
    10614228
  • 财政年份:
    2020
  • 资助金额:
    $ 65.04万
  • 项目类别:
The Clock is Ticking: Epigenetic Age Acceleration as a Biomarker of Uterine Function in Pregnancy
时钟在滴答作响:表观遗传年龄加速作为妊娠期子宫功能的生物标志物
  • 批准号:
    10630244
  • 财政年份:
    2020
  • 资助金额:
    $ 65.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了